ISI Stock Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.11 |
| 52 Week High | US$49.00 |
| 52 Week Low | US$31.29 |
| Beta | 0.40 |
| 1 Month Change | -3.20% |
| 3 Month Change | -18.32% |
| 1 Year Change | 14.03% |
| 3 Year Change | 8.08% |
| 5 Year Change | -42.52% |
| Change since IPO | 5.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| ISI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -5.1% | -2.0% |
| 1Y | 14.0% | -21.1% | -0.3% |
Return vs Industry: ISI exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: ISI exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| ISI volatility | |
|---|---|
| ISI Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ISI's share price has been volatile over the past 3 months.
Volatility Over Time: ISI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 927 | Brett Monia | www.ionispharma.com |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| ISI fundamental statistics | |
|---|---|
| Market cap | €5.57b |
| Earnings (TTM) | -€343.87m |
| Revenue (TTM) | €739.44m |
7.6x
P/S Ratio-16.3x
P/E RatioIs ISI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISI income statement (TTM) | |
|---|---|
| Revenue | US$787.65m |
| Cost of Revenue | US$907.10m |
| Gross Profit | -US$119.45m |
| Other Expenses | US$246.84m |
| Earnings | -US$366.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.51 |
| Gross Margin | -15.17% |
| Net Profit Margin | -46.50% |
| Debt/Equity Ratio | 462.5% |
How did ISI perform over the long term?
See historical performance and comparison